Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.580
-0.060 (-1.29%)
May 20, 2026, 4:00 PM EDT - Market closed

Radiopharm Theranostics Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
5337----
Market Cap Growth
60.01%-----
Enterprise Value
27.2616.190000
Last Close Price
4.584.64----
PS Ratio
4.9115.32----
PB Ratio
1.601.24----
P/TBV Ratio
-0.72----
EV/Sales Ratio
2.516.78----
Net Debt / Equity Ratio
--0.65-0.66-0.26-0.43-
Net Debt / EBITDA Ratio
-0.820.420.381.50-
Net Debt / FCF Ratio
-0.800.810.502.72-
Asset Turnover
-0.050.000.000-
Quick Ratio
-2.651.111.223.43-
Current Ratio
-2.671.301.233.46-
Return on Equity (ROE)
--109.20%-131.49%-63.77%-96.63%-
Return on Assets (ROA)
--48.29%-64.37%-43.61%-50.51%-
Return on Invested Capital (ROIC)
--85.27%-94.57%-61.65%-77.76%-
Return on Capital Employed (ROCE)
--60.59%-81.27%-50.26%-55.70%-
Buyback Yield / Dilution
-114.63%-438.49%-26.36%-68.74%-20138366.67%-
Total Shareholder Return
-114.63%-438.49%-26.36%-68.74%-20138366.67%-
Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q